Paolo Vicini
Affiliations: | University of Washington, Seattle, Seattle, WA |
Area:
Biomedical EngineeringGoogle:
"Paolo Vicini"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Yates JWT, Byrne H, Chapman SC, et al. (2020) Opportunities for quantitative translational modelling in Oncology. Clinical Pharmacology and Therapeutics |
| Milberg O, Gong C, Jafarnejad M, et al. (2019) A QSP Model for Predicting Clinical Responses to Monotherapy, Combination and Sequential Therapy Following CTLA-4, PD-1, and PD-L1 Checkpoint Blockade. Scientific Reports. 9: 11286 |
| Jafarnejad M, Gong C, Gabrielson E, et al. (2019) A Computational Model of Neoadjuvant PD-1 Inhibition in Non-Small Cell Lung Cancer. The Aaps Journal. 21: 79 |
| Wang H, Milberg O, Bartelink IH, et al. (2019) simulation of a clinical trial with anti-CTLA-4 and anti-PD-L1 immunotherapies in metastatic breast cancer using a systems pharmacology model. Royal Society Open Science. 6: 190366 |
| Gong C, Anders RA, Zhu Q, et al. (2018) Quantitative Characterization of CD8+ T Cell Clustering and Spatial Heterogeneity in Solid Tumors. Frontiers in Oncology. 8: 649 |
| Bartelink IH, Jones EF, Shahidi-Latham SK, et al. (2018) Tumor drug penetration measurements could be the neglected piece of the personalized cancer treatment puzzle. Clinical Pharmacology and Therapeutics |
| Baverel PG, Dubois VFS, Jin CY, et al. (2017) Population Pharmacokinetics of Durvalumab in Cancer Patients and Association with Longitudinal Biomarkers of Disease Status. Clinical Pharmacology and Therapeutics |
| Darwich AS, Ogungbenro K, Vinks AA, et al. (2017) Why has model-informed precision dosing not yet become common clinical reality? Lessons from the past and a roadmap for the future. Clinical Pharmacology and Therapeutics |
| Milberg O, Gong C, Wang B, et al. (2017) Abstract 4531: Systems pharmacology to predict cellular biomarkers and optimize mono- and combination-therapy regimens: Focusing on immune checkpoint targets PD-1, PD-L1 and CTLA-4 Cancer Research. 77: 4531-4531 |
| Spilker ME, Chen X, Visswanathan R, et al. (2016) Found in Translation: Maximizing the Clinical Relevance of Nonclinical Oncology Studies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |